Apollomics 6-K: Board reshuffle and new independent director

Rhea-AI Filing Summary

Apollomics, Inc. reported a change in its Board of Directors. On November 16, 2025, Mr. Po-Jen Hsueh resigned from the Board, with the company stating that his resignation was not related to any disagreement with the company.

On the same date, Dr. Ya-Chi (Claudia) Huang was appointed to the Board to fill the resulting vacancy and will also serve on the Audit Committee and the Nominating and Corporate Governance Committee. Following recent appointments, the Board now has seven members, five of whom are described as independent directors.

Dr. Huang brings experience in biotechnology investment, corporate governance, and R&D, including roles at Maxpro Ventures, Diamond Biofund, Fubon Securities, and multiple research institutions. The company also issued a press release on November 17, 2025 describing these board and committee changes, which is included as an exhibit.

		OMB APPROVAL
		OMB Number:				3235-0116
		Expires:		December 31, 2026
		Estimated average burden
		hours per response				8.7

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2025.

Commission File Number 001-41670

Apollomics, Inc.

(Translation of registrant’s name into English)

989 E. Hillsdale Blvd., Suite 220, Foster City, California 94404

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☒ Form 20-F   ☐ Form 40-F

Appointment and Departure of Certain Directors

On November 16, 2025, Mr. Po-Jen Hsueh resigned from the Board of Directors of the Company (the “Board”). Mr. Hsueh’s resignation was not related to any disagreement with the Company.

Pursuant to a meeting of the Board on November 16, 2025, Dr. Ya-Chi (Claudia) Huang was appointed to the Board to fill the vacancy resulting from Mr. Hsueh’s resignation. Dr. Ya-Chi (Claudia) Huang will also replace Mr. Po-Jen Hsueh as a member of the Company’s Audit Committee and Nominating and Corporate Governance Committee. Following these changes and the previously announced appointments of directors, the Company’s Board is comprised of the following seven members: Hung-Wen (Howard) Chen (Chairman), Hong-Jung (Moses) Chen, Yi-Kuei Chen, Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Ya-Chi (Claudia) Huang. Moses Chen, Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Ya-Chi (Claudia) Huang are independent directors.

Biographical Information of the New Director

Dr. Ya-Chi (Claudia) Huang brings to the Board extensive experience in biotechnology investment, corporate governance, and research and development across Taiwan’s biopharmaceutical industry.

Dr. Huang currently serves as Assistant Vice President at Maxpro Ventures, where she leads domestic and international investment activities. Since joining in 2024, she has successfully completed investments in multiple companies and manages their post-investment operations. She also serves as a director of AngenMed Therapeutics.

Previously, Dr. Huang served as Investment Manager at Diamond Biofund (6901.TW), where she independently completed multiple investments and oversaw post-investment management for all of Diamond’s portfolio companies. She participated in Diamond Biofund’s IPO on the Taiwan Stock Exchange in 2023. Earlier in her career, she was Deputy Manager in the Research Department at Fubon Securities Investment Services, where she evaluated over 150 unlisted biotech companies in Taiwan, China, and Hong Kong, and contributed to a significant increase in Fubon Securities’ investment banking profits.

Dr. Huang’s scientific background includes research positions at the National Health Research Institutes, Development Center for Biotechnology, and Academia Sinica. Her doctoral research on Epstein-Barr virus was published in Blood and received the Distinguished Thesis Prize in the 12th TienTe Lee Biomedical Award.

Dr. Huang holds a Ph.D. in Microbiology from National Taiwan University College of Medicine and an M.S. in Biological Sciences from National Sun Yat-sen University.

Press Releases

On November 17, 2025, the Company issued a press release announcing changes to its Board and composition of committees. The press release is attached here as Exhibit 99.1.

The information contained in this Form 6-K relating to the changes in the Company’s Board of Directors is incorporated by reference into the Company’s registration statements under the Securities Act, including its registration statements on Form S-8 (File No. 333-272559) and Form F-3 (File Nos. 333-278430, 333-278431 and 333-279549), and shall be a part thereof, to the extent not superseded by documents or reports subsequently filed or furnished.

[EXHIBITS]

Exhibit No.		Description
99.1		Press Release - Apollomics Announces changes to its Board and composition of committees

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

				APOLLOMICS INC.
/Date: November 17, 2025				By:		/s/ Peter Lin
				Name:		Peter Lin
				Title:		Chief Financial Officer

FAQ

What board change did Apollomics (APLM) report in this Form 6-K?

Apollomics reported that Mr. Po-Jen Hsueh resigned from its Board of Directors on November 16, 2025, and that his resignation was not related to any disagreement with the company.

Who was appointed to the Apollomics (APLM) Board to replace Mr. Hsueh?

Dr. Ya-Chi (Claudia) Huang was appointed to the Board on November 16, 2025 to fill the vacancy created by Mr. Hsueh’s resignation.

What committee roles will Dr. Ya-Chi (Claudia) Huang have at Apollomics (APLM)?

Dr. Huang will replace Mr. Po-Jen Hsueh as a member of Apollomics’ Audit Committee and Nominating and Corporate Governance Committee.

How many directors does Apollomics (APLM) have after these changes and how many are independent?

After these changes and previously announced appointments, Apollomics’ Board consists of seven members, of whom five are described as independent directors.

What relevant experience does Dr. Ya-Chi (Claudia) Huang bring to the Apollomics (APLM) Board?

Dr. Huang has extensive experience in biotechnology investment, corporate governance, and research and development, with roles at Maxpro Ventures, Diamond Biofund, Fubon Securities, and several biomedical research institutions.

Did Apollomics (APLM) issue a press release about the board and committee changes?

Yes. On November 17, 2025, Apollomics issued a press release announcing the changes to its Board and committee composition, which is attached as Exhibit 99.1.

Are these board changes incorporated into Apollomics’ existing registration statements?

Yes. The information about changes in the Board of Directors is incorporated by reference into Apollomics’ registration statements under the Securities Act, including its Forms S-8 and F-3.